Related Experiment Video
Updated: Jun 19, 2026
Diffusion Tensor Magnetic Resonance Imaging in the Analysis of Neurodegenerative Diseases
Published on: July 28, 2013
Deferiprone-induced arthropathy in thalassemia: MRI findings in a case
Gyan Chand1, Veena Chowdhury, A Manchanda
1Department of Radiodiagnosis, Maulana Azad Medical College, New Delhi-110 002, India.
Abstract:
Arthropathy is a well known side effect of the iron chelator deferiprone (L1); however, the imaging findings in deferiprone-induced arthropathy are not well known. In this article, we describe the typical radiographic and MRI findings in a patient receiving regular blood transfusions who developed arthropathy after long-term therapy with the oral iron chelator deferiprone (L1). Deferiprone primarily affects the articular cartilage and the changes include synovial thickening, articular cartilage thickening, and subchondral bone erosions.
Insights
Deferiprone (L1) can cause joint problems. Imaging shows this arthropathy affects cartilage, causing thickening and bone erosion in patients on long-term iron chelation therapy.
Area of Science:
- Rheumatology
- Radiology
- Pharmacology
Background:
- Deferiprone (L1) is an oral iron chelator used in patients requiring regular blood transfusions.
- Arthropathy is a recognized side effect of deferiprone therapy.
- Imaging findings associated with deferiprone-induced arthropathy are not well-documented.
Observation:
- This article details the radiographic and MRI findings in a patient with deferiprone-induced arthropathy.
- The patient had a history of regular blood transfusions and long-term deferiprone treatment.
- The observed arthropathy primarily impacted the articular cartilage.
Findings:
- Radiographic and MRI revealed synovial thickening.
- Articular cartilage exhibited thickening.
- Subchondral bone erosions were present.
Implications:
- Understanding these imaging findings is crucial for diagnosing deferiprone-induced arthropathy.
- Early detection through imaging may allow for timely intervention.
- This highlights the importance of monitoring joint health in patients on long-term deferiprone therapy.
